MXPA05007883A - Proceso para producir una preparacion recubierta. - Google Patents

Proceso para producir una preparacion recubierta.

Info

Publication number
MXPA05007883A
MXPA05007883A MXPA05007883A MXPA05007883A MXPA05007883A MX PA05007883 A MXPA05007883 A MX PA05007883A MX PA05007883 A MXPA05007883 A MX PA05007883A MX PA05007883 A MXPA05007883 A MX PA05007883A MX PA05007883 A MXPA05007883 A MX PA05007883A
Authority
MX
Mexico
Prior art keywords
producing coated
coated preparation
preparation
producing
pioglitazone hydrochloride
Prior art date
Application number
MXPA05007883A
Other languages
English (en)
Inventor
Koike Masahiko
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32830627&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA05007883(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MXPA05007883A publication Critical patent/MXPA05007883A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion esta dirigida a proporcionar un proceso para la produccion de una preparacion recubierta con clorhidrato de pioglitazona que es util como un remedio para la diabetes, etc., y tiene excelentes caracteristicas de preparacion tales como la propiedad de disolucion del clorhidrato de pioglitazona.
MXPA05007883A 2003-01-29 2004-01-28 Proceso para producir una preparacion recubierta. MXPA05007883A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2003020925 2003-01-29
JP2003276894 2003-07-18
JP2004001128 2004-01-06
PCT/JP2004/000754 WO2004067001A1 (ja) 2003-01-29 2004-01-28 被覆製剤の製造法

Publications (1)

Publication Number Publication Date
MXPA05007883A true MXPA05007883A (es) 2005-09-21

Family

ID=32830627

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05007883A MXPA05007883A (es) 2003-01-29 2004-01-28 Proceso para producir una preparacion recubierta.

Country Status (14)

Country Link
US (1) US7976853B2 (es)
EP (1) EP1588708A4 (es)
KR (1) KR101114808B1 (es)
AU (1) AU2004208606B2 (es)
BR (1) BRPI0407074A (es)
CA (1) CA2514539C (es)
CR (1) CR7929A (es)
IL (1) IL169870A (es)
MA (1) MA27624A1 (es)
MX (1) MXPA05007883A (es)
NO (1) NO20053965L (es)
NZ (1) NZ541749A (es)
PL (1) PL377403A1 (es)
WO (1) WO2004067001A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
AU2004285354B2 (en) 2003-10-31 2009-09-17 Takeda Pharmaceutical Company Limited Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
JP4739189B2 (ja) 2004-04-14 2011-08-03 武田薬品工業株式会社 固形製剤
GB0423964D0 (en) * 2004-10-28 2004-12-01 Jagotec Ag Dosage form
TWI274889B (en) * 2005-10-06 2007-03-01 Elan Microelectronics Corp Resistive touch screen measurement system
RU2426530C2 (ru) 2005-12-22 2011-08-20 Такеда Фармасьютикал Компани Лимитед Твердый препарат
ZA200901075B (en) * 2006-08-10 2010-05-26 Takeda Pharmaceutical Pharmaceutical composition
JP5284968B2 (ja) * 2007-02-01 2013-09-11 武田薬品工業株式会社 アログリプチンおよびピオグリタゾンを含有する固形製剤
US20080064701A1 (en) * 2007-04-24 2008-03-13 Ramesh Sesha Anti-diabetic combinations
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
TW200914006A (en) * 2007-07-12 2009-04-01 Takeda Pharmaceutical Coated preparation
KR101617243B1 (ko) 2007-07-31 2016-05-02 라이프스캔, 인코포레이티드 인간 배아 줄기 세포의 분화
KR101592182B1 (ko) 2007-11-27 2016-02-05 라이프스캔, 인코포레이티드 인간 배아 줄기 세포의 분화
KR101731474B1 (ko) 2008-02-21 2017-05-11 얀센 바이오테크 인코포레이티드 세포 부착, 배양 및 탈리를 위한 방법, 표면 개질 플레이트 및 조성물
US8551524B2 (en) * 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
EP2190417A2 (en) * 2008-03-26 2010-06-02 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions comprising insulin sensitizer and insulin secretagogue
PL2942392T3 (pl) 2008-06-30 2019-02-28 Janssen Biotech, Inc Różnicowanie pluripotencjalnych komórek macierzystych
US9234178B2 (en) 2008-10-31 2016-01-12 Janssen Biotech, Inc. Differentiation of human pluripotent stem cells
JP5719305B2 (ja) 2008-11-20 2015-05-13 ヤンセン バイオテツク，インコーポレーテツド 平面支持体上での細胞付着及び培養のための方法及び組成物
AU2009316580B2 (en) 2008-11-20 2016-04-14 Janssen Biotech, Inc. Pluripotent stem cell culture on micro-carriers
WO2011011300A2 (en) 2009-07-20 2011-01-27 Centocor Ortho Biotech Inc. Differentiation of human embryonic stem cells
US9150833B2 (en) 2009-12-23 2015-10-06 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
RU2607380C2 (ru) 2010-03-01 2017-01-10 Янссен Байотек, Инк. Способы очистки клеток, производных от плюрипотентных стволовых клеток
WO2011143299A2 (en) 2010-05-12 2011-11-17 Centocor Ortho Biotech Inc. Differentiation of human embryonic stem cells
US9506036B2 (en) 2010-08-31 2016-11-29 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
EP3211070A1 (en) 2010-08-31 2017-08-30 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
JP2013538807A (ja) 2010-09-01 2013-10-17 ルピン・リミテッド メトホルミンおよびピオグリタゾンを含む医薬組成物
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
RU2705001C2 (ru) 2011-12-22 2019-11-01 Янссен Байотек, Инк. Дифференцировка эмбриональных стволовых клеток человека в одногормональные инсулинположительные клетки
CN104160018A (zh) 2012-03-07 2014-11-19 詹森生物科技公司 用于扩增和维持多能干细胞的成分确定的培养基
ES2690118T3 (es) 2012-06-08 2018-11-19 Janssen Biotech, Inc. Diferenciación de células madre embrionarias humanas en células endocrinas pancreáticas
EP2674149B1 (en) * 2012-06-15 2017-10-04 Shin-Etsu Chemical Co., Ltd. Method of preparing composite granule comprising low-substituted hydroxypropyl cellulose and rapid release preparation
BR112015015770A2 (pt) 2012-12-31 2017-07-11 Janssen Biotech Inc cultivo de células-tronco embrionárias humanas na interface ar-líquido para diferenciação em células pancreáticas endócrinas
KR101942769B1 (ko) 2012-12-31 2019-01-28 얀센 바이오테크 인코포레이티드 Hb9 조절제를 사용하는 인간 배아 줄기세포의 췌장 내분비 세포로의 분화
CA2896750A1 (en) 2012-12-31 2014-07-03 Janssen Biotech, Inc. Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
KR101711876B1 (ko) * 2013-06-17 2017-03-03 닛뽕소다 가부시키가이샤 히드록시알킬 셀룰로오스를 함유하는 코팅제
KR101597004B1 (ko) * 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
WO2015175307A1 (en) 2014-05-16 2015-11-19 Janssen Biotech, Inc. Use of small molecules to enhance mafa expression in pancreatic endocrine cells
MA45479A (fr) 2016-04-14 2019-02-20 Janssen Biotech Inc Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
RU2690677C1 (ru) * 2018-06-27 2019-06-05 Георгий Георгиевич Чумбуридзе Стабилизированная композиция, обладающая противовирусной, противоопухолевой, иммуномодулирующей, актопротекторной, антимутагенной и антиоксидантной активностью
CN112461947B (zh) * 2020-10-27 2022-06-28 山东省药学科学院 一种盐酸吡格列酮片溶出曲线的测定方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5179716A (en) * 1974-12-28 1976-07-12 Shinetsu Chemical Co Kokeiiyakuseizaino seizohoho
DE3720757A1 (de) 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
ES2124794T3 (es) * 1992-10-09 1999-02-16 Kanegafuchi Chemical Ind Procedimiento para producir granulados finos.
US5651983A (en) * 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
EP0719140B1 (en) 1993-09-15 2007-10-31 Daiichi Sankyo Company, Limited Use of thiazolidinediones to prevent or delay onset of niddm
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US6291495B1 (en) 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6153632A (en) 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
US20020004515A1 (en) 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
ATE355840T1 (de) 1997-06-18 2007-03-15 Smithkline Beecham Plc Behandlung der diabetes mit thiazolidindione und metformin
JP4523153B2 (ja) 1998-03-19 2010-08-11 ブリストル−マイヤーズ スクイブ カンパニー 易溶性薬物の二層性放出制御送達システムおよび方法
WO2000016776A1 (fr) * 1998-09-18 2000-03-30 Takeda Chemical Industries, Ltd. Preparations a administrer par voie buccale a liberation lente
AU6228799A (en) * 1998-10-26 2000-05-15 Tanabe Seiyaku Co., Ltd. Sustained-release particles
DZ2937A1 (fr) 1998-11-12 2004-03-15 Smithkline Beecham Plc Compositions nouvelles de sensibilidants à l'insuline.
WO2000028989A1 (en) 1998-11-12 2000-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6168806B1 (en) 1999-03-05 2001-01-02 Fang-Yu Lee Orally administrable nifedipine pellet and process for the preparation thereof
JP2003514011A (ja) * 1999-11-16 2003-04-15 スミスクライン ビーチャム パブリック リミテッド カンパニー チアゾリジンジオン−塩酸メトホルミンを含む医薬組成物
AR030920A1 (es) 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
EP1254667A4 (en) * 2000-02-10 2003-03-12 Takeda Chemical Industries Ltd MEDICINE COMPRISING A COMBINATION
US6780432B1 (en) 2000-05-01 2004-08-24 Aeropharm Technology, Inc. Core formulation
US6403121B1 (en) * 2000-05-01 2002-06-11 Aeropharm Technology Incorporated Core formulation
US6524621B2 (en) 2000-05-01 2003-02-25 Aeropharm Technology Inc. Core formulation
US6610272B1 (en) * 2000-05-01 2003-08-26 Aeropharm Technology Incorporated Medicinal aerosol formulation
JP2001342185A (ja) * 2000-06-02 2001-12-11 Nichiko Pharmaceutical Co Ltd フィルムコーティングされた塩酸ラニチジン錠剤
EP1738751B1 (en) 2001-01-12 2011-05-11 Sun Pharma Advanced Research Company Ltd Spaced drug delivery system
EP1364650A1 (en) * 2001-01-30 2003-11-26 Teijin Limited Medicinal composition
CA2453775A1 (en) 2001-07-10 2003-01-23 Kos Life Sciences, Inc. Core formulation comprising pioglitazone hydrochloride and a biguanide
US20030187074A1 (en) 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
KR100897890B1 (ko) 2002-06-17 2009-05-18 인벤티아 헬스케어 피브이티. 엘티디. 티아졸리딘디온 및 바이구아나이드를 함유하는 다층 정제및 그의 제조 방법
AU2003281181A1 (en) 2002-07-11 2004-02-02 Takeda Pharmaceutical Company Limited Process for producing coated preparation
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
KR20120034211A (ko) * 2002-09-20 2012-04-10 안드렉스 랩스 엘엘씨 약제학적 정제
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
IN192749B (es) * 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
AU2003282377A1 (en) 2003-02-05 2004-08-30 Ipca Laboratories Limited Dual release anti-diabetic drugs and process of production thereof

Also Published As

Publication number Publication date
CA2514539A1 (en) 2004-08-12
KR101114808B1 (ko) 2012-02-15
NO20053965L (no) 2005-08-25
AU2004208606A1 (en) 2004-08-12
EP1588708A1 (en) 2005-10-26
PL377403A1 (pl) 2006-02-06
BRPI0407074A (pt) 2006-01-24
EP1588708A4 (en) 2006-03-01
CA2514539C (en) 2012-03-06
MA27624A1 (fr) 2005-11-01
US20060141128A1 (en) 2006-06-29
AU2004208606B2 (en) 2009-09-24
IL169870A (en) 2012-07-31
NZ541749A (en) 2009-06-26
CR7929A (es) 2005-11-28
KR20050096958A (ko) 2005-10-06
US7976853B2 (en) 2011-07-12
WO2004067001A1 (ja) 2004-08-12

Similar Documents

Publication Publication Date Title
MXPA05007883A (es) Proceso para producir una preparacion recubierta.
TW200718420A (en) Formulation of a thienopyridine platelet aggregation inhibitor
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
PL1891004T3 (pl) Pentafluorosulfanylo-podstawiony związek i jego zastosowanie do wytwarzania środków leczniczych
TW200603818A (en) Conjugates of hydroxyethyl starch and erythropoietin
WO2008046581A3 (de) Substituierte tetrahydropyrrolopyrazin-verbindungen als inhibitoren der monoaminwiederaufnahme und deren verwendung in arzeimitteln
TW200716203A (en) Manufacturing process for tigecycline
GEP20084367B (en) Diazepinoindole derivatives as kinase inhibitors
HK1112238A1 (en) Substituted benzo(d)isoxazol-3-yl amine compounds as analgesics
JO2985B1 (ar) مثبطات كينازmapk/erk
EP2070935A4 (en) NOVEL COMPOUND, COMPOSITION COMPRISING SAME, AND PROCESS FOR PRODUCING POLYMERIZABLE AMIDE
AU2003269794A1 (en) Process for preparing superhydrophobic surface compositions, surfaces obtained by said process and use of them
ZA200702424B (en) Method for the synthesis of zeolite beta with diethylentriamine
NZ579928A (en) Fluorinated derivatives of deferiprone
WO2008017074A3 (en) Dyes and precursors and conjugates thereof
AU2003258187A1 (en) Enzymatic processes for the production of 4-substituted 3-hydroxybutyric acid derivatives
WO2006024389A3 (de) Biphenylthiazolcarboxamide
MXPA05011962A (es) Oxiarenos substituidos.
MXPA05013751A (es) Procedimiento e intermediarios para la preparacion de 3-(amino)-3-ciclobutilmetil-2-hidroxi-propionamida o sus sales.
TW200621703A (en) Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
TW200613308A (en) Cyclobutanetetracarboxylate compound and preparation method thereof
MX2008011576A (es) Compuestos de imidazo[2,1-b]tiazol sustituidos y su uso para la produccion de farmacos.
TW200740769A (en) Novel process
EP1788004A4 (en) NOVEL MODIFIED POLYMER, PROCESS FOR MANUFACTURING THE SAME, AND USE OF THE SAME NEW MODIFIED POLYMER
UA86015C2 (ru) Способ получения твердой лекарственной формы с покрытием

Legal Events

Date Code Title Description
FG Grant or registration